Intra-arterial therapies (IATs) play a major role in the treatment of patients with unresectable
hepatocellular carcinoma. Over the last three decades, multiple loco-regional approaches …

Hepatocellular carcinoma (HCC) is a chronic liver disease that is highly fatal if not detected
and treated early. The incidence and death rate of HCC have been increasing in recent …

Objective This trial compared the efficacy and safety of transarterial chemoembolisation
(TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint …

Background & Aims Transarterial chemoembolization with doxorubicin-eluting beads (DC
Bead®; DEB-TACE) is effective in patients with Barcelona clinic liver cancer stage B …

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for
cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel …

Background & Aims Sorafenib is first-line standard of care for patients with advanced
hepatocellular carcinoma (HCC), yet it confers limited survival benefit. Therefore, we aimed …

Sorafenib is the first and only po administrated drug currently approved to treat advanced
hepatocellular carcinoma (HCC). However, concerns have been raised about sorafenib …

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular
Carcinoma Login to Submission Gut and Liver 2021 Impact Factor 4.321 Indexed In …

This phase II, investigator‐initiated, prospective single‐arm multinational study
(ClinicalTrials. gov registration NCT00990860) evaluated sorafenib in combination with …

Purpose To compare the time to progression (TTP) and overall survival (OS) in patients with
advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment …